In the top February M&A by deal value, Abbott entered into a definitive agreement to acquire Cardiovascular Systems for $20 per share (a 44% premium), or $890m. Founded in 1989, Cardiovascular Systems is a medical device company focused on the development and commercialization of innovative solutions for treating complex peripheral vascular disease and coronary artery disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. CSI also has an early-stage pipeline of complementary vascular intervention devices in development. Financing reached $3.9bn in biopharma, $296m in device, and $108m in diagnostics.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?